Speaking about the importance of human challenge trials, the article coincides with the launch of Doherty Clinical Trials' facility in East Melbourne.
Doherty Clinical Trials' Chief Medical Officer, Professor James McCarthy and CEO, Dr Andrew Brockway (pictured above) were this week featured in The Age explaining the importance of human challenge trials, how they're administered and the valuable insights they can deliver to further advance medical research and help Victoria, and potentially the world, prepare for the next pandemic.
Coinciding with the launch and unveiling of the facility, currently based in East Melbourne, the article also speaks with Doherty Institute director and Doherty Clinical Trials board member, Professor Sharon Lewin, who articulated the focus of the unit - the first purpose-built human challenge facility in the Southern Hemisphere.
You can read the full article here.
Image taken from The Age article 'Virus volunteers to help Melbourne’s new human trials clinic prepare for the next pandemic', captured by Paul Jeffers.
Doherty Clinical Trials Limited is proud to announce the commencement of the CHIVAS-M1 study (Controlled Human Infection for Vaccination Against Streptococcus pyogenes M1UK), which will help drive medical research and development of a vaccine against Streptococcus pyogenes, otherwise known as Strep A.
Senior Lab Manager, Vanessa Mollard represented Doherty Clinical Trials at the forum in Canberra
Dr Andrew Brockway's panel, 'Clinical Trials in Australia: Performance, Competitive Advantages, Challenges and Evolving Policy' at AusBiotech 2024
Highlighting the vital work of Doherty Clinical Trials and sharing why participants find it so rewarding.
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}